Thr530
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr530  -  SIRT1 (human)

Site Information
YLSELPPtPLHVsED   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 6006905
Available spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 1 , 2 , 11 , 46 ) , mass spectrometry ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 46 ) , mass spectrometry (in vitro) ( 45 ) , mutation of modification site ( 11 , 45 , 46 ) , phospho-antibody ( 1 , 2 , 11 , 46 ) , western blotting ( 1 , 2 , 11 , 46 )
Disease tissue studied:
bone cancer ( 1 , 2 ) , colorectal cancer ( 2 ) , colorectal carcinoma ( 2 ) , gastric cancer ( 35 , 40 , 41 ) , gastric carcinoma ( 35 , 40 , 41 ) , leukemia ( 32 , 42 , 43 ) , chronic lymphocytic leukemia ( 32 ) , chronic myelogenous leukemia ( 42 , 43 ) , lung cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 25 , 26 , 27 , 28 , 29 , 36 , 37 , 38 , 39 ) , non-small cell lung cancer ( 4 , 5 , 6 , 8 , 9 , 10 , 12 , 13 , 25 , 26 , 27 , 28 , 29 , 36 , 37 , 38 ) , non-small cell lung adenocarcinoma ( 4 , 5 , 6 , 7 , 8 , 9 , 10 , 25 , 27 , 28 ) , non-small cell large cell lung carcinoma ( 5 , 8 , 26 ) , non-small cell squamous cell lung carcinoma ( 7 , 29 ) , small-cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 4 , 12 ) , Cal-12T (pulmonary) ( 10 ) , Calu-3 (pulmonary) ( 6 , 25 ) , DMS153 (pulmonary) ( 9 ) , DMS53 (pulmonary) ( 3 ) , DV-90 (pulmonary) ( 27 ) , ES (stem) ( 46 ) , HCC15 (pulmonary) ( 7 ) , HCC44 (pulmonary) ( 10 ) , HCC78 (pulmonary) ( 8 ) , HCC827 (pulmonary) ( 6 ) , HCT116 (intestinal) ( 2 ) , HEK293T (epithelial) ( 1 , 2 , 11 , 45 , 46 ) , HeLa (cervical) ( 2 ) , hepatocyte-liver ( 11 ) , Jurkat (T lymphocyte) ( 16 , 34 , 44 ) , K562 (erythroid) ( 42 , 43 ) , LOU-NH91 (squamous) ( 7 ) , lung ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 36 , 37 , 38 , 39 ) , MEF (fibroblast) ( 46 ) , MKN-45 (gastric) ( 35 , 40 , 41 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1355 (pulmonary) ( 4 ) , NCI-H1437 (pulmonary) ( 9 , 10 ) , NCI-H1650 (pulmonary) ( 6 ) , NCI-H1666 (pulmonary) ( 10 ) , NCI-H1703 (squamous) ( 7 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1781 (pulmonary) ( 8 ) , NCI-H1792 (pulmonary) ( 4 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H1975 (pulmonary) ( 6 ) , NCI-H2073 (pulmonary) ( 7 , 9 ) , NCI-H209 (pulmonary) ( 9 ) , NCI-H2106 (pulmonary) ( 6 ) , NCI-H2228 (pulmonary) ( 8 ) , NCI-H23 (pulmonary) ( 4 ) , NCI-H2342 (pulmonary) ( 7 , 28 ) , NCI-H2405 (pulmonary) ( 10 ) , NCI-H3122 (pulmonary) ( 8 ) , NCI-H3255 (pulmonary) ( 13 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H441 (pulmonary) ( 4 ) , NCI-H446 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 5 , 26 ) , NCI-H520 (squamous) ( 29 ) , NCI-H526 (pulmonary) ( 3 ) , NCI-H661 (pulmonary) ( 8 ) , NCI-H69 (pulmonary) ( 3 ) , NCI-H82 (pulmonary) ( 3 ) , NCI-H838 (pulmonary) ( 9 ) , U2OS (bone cell) ( 1 , 2 )

Upstream Regulation
Regulatory protein:
AMPKA1 (human) ( 2 , 11 ) , CDK1 (human) ( 1 )
Putative in vivo kinases:
JNK1 (human) ( 45 )
Kinases, in vitro:
CDK1 (human) ( 46 ) , JNK1 (human) ( 45 )
Treatments:
acadesine ( 11 ) , anisomycin ( 45 ) , compound_C ( 11 ) , glucose_starvation ( 2 , 11 ) , SP600125 ( 45 )

Downstream Regulation
Effects of modification on SIRT1:
acetylation ( 46 ) , enzymatic activity, induced ( 45 , 46 ) , intracellular localization ( 1 , 2 , 45 ) , molecular association, regulation ( 2 , 11 )
Effects of modification on biological processes:
autophagy, induced ( 11 ) , cell cycle regulation ( 1 , 46 ) , cytoskeletal reorganization ( 1 )
Induce interaction with:
ATG7 (human) ( 11 ) , PABP 1 (human) ( 2 )
Inhibit interaction with:
REG3G (human) ( 11 )

References 

1

Ling H, et al. (2018) Histone Deacetylase SIRT1 Targets Plk2 to Regulate Centriole Duplication. Cell Rep 25, 2851-2865.e3
30517871   Curated Info

2

Shan P, et al. (2017) SIRT1 Functions as a Negative Regulator of Eukaryotic Poly(A)RNA Transport. Curr Biol 27, 2271-2284.e5
28756945   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Dong S, et al. (2013) The REG╬│ proteasome regulates hepatic lipid metabolism through inhibition of autophagy. Cell Metab 18, 380-91
24011073   Curated Info

12

Rikova K (2012) CST Curation Set: 16144; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]
Curated Info

13

Rikova K (2012) CST Curation Set: 16142; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

14

Rikova K (2012) CST Curation Set: 13915; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -;
Curated Info

15

Rikova K (2012) CST Curation Set: 13916; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -;
Curated Info

16

Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

17

Rikova K (2011) CST Curation Set: 13113; Year: 2011; Biosample/Treatment: cell line, MGH-1/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

18

Rikova K (2011) CST Curation Set: 13114; Year: 2011; Biosample/Treatment: cell line, MGH-2/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

19

Rikova K (2011) CST Curation Set: 13115; Year: 2011; Biosample/Treatment: cell line, MGH-3/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

20

Rikova K (2011) CST Curation Set: 13116; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

21

Rikova K (2011) CST Curation Set: 13117; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

22

Rikova K (2011) CST Curation Set: 13118; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

23

Rikova K (2011) CST Curation Set: 13119; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

24

Rikova K (2011) CST Curation Set: 13122; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

25

Rikova K (2011) CST Curation Set: 10887; Year: 2011; Biosample/Treatment: cell line, Calu-3/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

26

Rikova K (2011) CST Curation Set: 10893; Year: 2011; Biosample/Treatment: cell line, NCI-H460/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

27

Rikova K (2011) CST Curation Set: 10895; Year: 2011; Biosample/Treatment: cell line, DV-90/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

28

Rikova K (2011) CST Curation Set: 10885; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

29

Rikova K (2011) CST Curation Set: 10911; Year: 2011; Biosample/Treatment: cell line, NCI-H520/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

30

Rikova K (2010) CST Curation Set: 10041; Year: 2010; Biosample/Treatment: cell line, DFCI ERC17/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

31

Rikova K (2010) CST Curation Set: 10037; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11 serum free/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

32

Rikova K (2010) CST Curation Set: 10035; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11/untreated; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

33

Rikova K (2010) CST Curation Set: 10039; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

34

Rikova K (2010) CST Curation Set: 9774; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

35

Rikova K (2010) CST Curation Set: 9773; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

36

Rikova K (2010) CST Curation Set: 9452; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

37

Rikova K (2010) CST Curation Set: 9455; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

38

Rikova K (2010) CST Curation Set: 9468; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

39

Rikova K (2010) CST Curation Set: 9469; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

40

Rikova K (2010) CST Curation Set: 9329; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

41

Rikova K (2010) CST Curation Set: 9328; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

42

Rikova K (2010) CST Curation Set: 9327; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

43

Rikova K (2010) CST Curation Set: 9326; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

44

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

45

Nasrin N, et al. (2009) JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One 4, e8414
20027304   Curated Info

46

Sasaki T, et al. (2008) Phosphorylation regulates SIRT1 function. PLoS One 3, e4020
19107194   Curated Info